{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:30:38Z","timestamp":1792740638402,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI158543"],"award-info":[{"award-number":["R01AI158543"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["U24AI171008"],"award-info":[{"award-number":["U24AI171008"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"U.S. Department of Health & Human Services | Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["NU58DP006956"],"award-info":[{"award-number":["NU58DP006956"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI158543"],"award-info":[{"award-number":["R01AI158543"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["2019PT320003"],"award-info":[{"award-number":["2019PT320003"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82460015"],"award-info":[{"award-number":["No. 82460015"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-61613-4","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T16:09:23Z","timestamp":1752595763000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Evaluating the safety of XBB.1.5-containing COVID-19 mRNA vaccines using a self-controlled case series study"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0595-4335","authenticated-orcid":false,"given":"Yuanyi","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6366-8206","authenticated-orcid":false,"given":"Lili","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2999-0103","authenticated-orcid":false,"given":"Jie","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianwei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9189-9661","authenticated-orcid":false,"given":"Yongqun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On Behalf of N3C Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Chute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"61613_CR1","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"61613_CR2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"61613_CR3","unstructured":"FDA. FDA Takes Action on Updated mRNA COVID-19 Vaccines to Better Protect Against Currently Circulating Variants. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-takes-action-updated-mrna-covid-19-vaccines-better-protect-against-currently-circulating (2024)."},{"key":"61613_CR4","doi-asserted-by":"publisher","unstructured":"Huiberts, A. J. et al. Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024. Euro Surveill. 29, https:\/\/doi.org\/10.2807\/1560-7917.es.2024.29.10.2400109 (2024).","DOI":"10.2807\/1560-7917.es.2024.29.10.2400109"},{"key":"61613_CR5","doi-asserted-by":"publisher","first-page":"2270069","DOI":"10.1080\/22221751.2023.2270069","volume":"12","author":"JN Faraone","year":"2023","unstructured":"Faraone, J. N. et al. Immune evasion and membrane fusion of SARS-CoV-2 XBB subvariants EG. 5.1 and XBB. 2.3. Emerg. Microbes Infect. 12, 2270069 (2023).","journal-title":"Emerg. Microbes Infect."},{"key":"61613_CR6","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1016\/S2666-5247(22)00335-4","volume":"4","author":"X Zhang","year":"2023","unstructured":"Zhang, X. et al. Omicron sublineage recombinant XBB evades neutralising antibodies in recipients of BNT162b2 or CoronaVac vaccines. Lancet Microbe 4, e131 (2023).","journal-title":"Lancet Microbe"},{"key":"61613_CR7","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.cell.2022.12.018","volume":"186","author":"Q Wang","year":"2023","unstructured":"Wang, Q. et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell 186, 279\u2013286 (2023).","journal-title":"Cell"},{"key":"61613_CR8","unstructured":"CDC. COVID-19 Vaccinations Administered in Pharmacies and Medical Offices*, Adults 18 Years and Older, United States. https:\/\/www.cdc.gov\/covidvaxview\/weekly-dashboard\/vaccinations-administered-pharmacies-medical.html?CDC_AAref_Val=https:\/\/www.cdc.gov\/vaccines\/imz-managers\/coverage\/covidvaxview\/interactive\/adult-vaccinations-administered.html (2024)."},{"key":"61613_CR9","unstructured":"Centers for Disease Control and Prevention. Vaccine Adverse Event Reporting System (VAERS). https:\/\/vaers.hhs.gov\/about.html (2024)."},{"key":"61613_CR10","unstructured":"European Medicines Agency. EudraVigilance system overview https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/pharmacovigilance-research-development\/eudravigilance\/eudravigilance-system-overview (2024)."},{"key":"61613_CR11","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/00006454-200404000-00002","volume":"23","author":"F Varricchio","year":"2004","unstructured":"Varricchio, F. et al. Understanding vaccine safety information from the vaccine adverse event reporting system. Pediatr. Infect. Dis. J. 23, 287\u2013294 (2004).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"61613_CR12","doi-asserted-by":"publisher","first-page":"n1416","DOI":"10.1136\/bmj.n1416","volume":"373","author":"V Lo Re","year":"2021","unstructured":"Lo Re, V. et al. Global covid-19 vaccine rollout and safety surveillance\u2014how to keep pace. BMJ 373, n1416 (2021).","journal-title":"BMJ"},{"key":"61613_CR13","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1542\/peds.99.6.765","volume":"99","author":"RT Chen","year":"1997","unstructured":"Chen, R. T. et al. Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. Pediatrics 99, 765\u2013773 (1997).","journal-title":"Pediatrics"},{"key":"61613_CR14","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1001\/jama.2021.14808","volume":"326","author":"KG Blumenthal","year":"2021","unstructured":"Blumenthal, K. G., Phadke, N. A. & Bates, D. W. Safety surveillance of COVID-19 mRNA vaccines through the Vaccine Safety Datalink. JAMA 326, 1375\u20131377 (2021).","journal-title":"JAMA"},{"key":"61613_CR15","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1001\/jama.2021.15072","volume":"326","author":"NP Klein","year":"2021","unstructured":"Klein, N. P. et al. Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA 326, 1390\u20131399 (2021).","journal-title":"JAMA"},{"key":"61613_CR16","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/S1473-3099(22)00054-8","volume":"22","author":"HG Rosenblum","year":"2022","unstructured":"Rosenblum, H. G. et al. Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe. Lancet Infect. Dis. 22, 802\u2013812 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"61613_CR17","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s40121-022-00742-5","volume":"12","author":"M-T Lee","year":"2023","unstructured":"Lee, M.-T. et al. Safety profiles of mRNA COVID-19 vaccines using World Health Organization Global Scale Database (VigiBase): a latent class analysis. Infect. Dis. Ther. 12, 443\u2013458 (2023).","journal-title":"Infect. Dis. Ther."},{"key":"61613_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.669010","volume":"12","author":"G Chen","year":"2021","unstructured":"Chen, G. et al. COVID-19 mRNA vaccines are generally safe in the short term: a vaccine vigilance real-world study says. Front. immunol. 12, 669010 (2021).","journal-title":"Front. immunol."},{"key":"61613_CR19","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","volume":"385","author":"SJ Thomas","year":"2021","unstructured":"Thomas, S. J. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. N. Engl. J. Med. 385, 1761\u20131773 (2021).","journal-title":"N. Engl. J. Med."},{"key":"61613_CR20","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1016\/j.vaccine.2021.02.007","volume":"39","author":"L Chu","year":"2021","unstructured":"Chu, L. et al. A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. Vaccine 39, 2791\u20132799 (2021).","journal-title":"Vaccine"},{"key":"61613_CR21","unstructured":"CDC. Coronavirus Disease 2019 (COVID-19) Vaccine Safety, https:\/\/www.cdc.gov\/vaccine-safety\/vaccines\/covid-19.html (2024)."},{"key":"61613_CR22","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/jamia\/ocaa196","volume":"28","author":"MA Haendel","year":"2021","unstructured":"Haendel, M. A. et al. The National COVID Cohort Collaborative (N3C): Rationale, design, infrastructure, and deployment. J. Am. Med. Inform. Assoc. 28, 427\u2013443 (2021).","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"61613_CR23","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.jaci.2017.12.971","volume":"141","author":"MM McNeil","year":"2018","unstructured":"McNeil, M. M. & DeStefano, F. Vaccine-associated hypersensitivity. J. Allergy Clin. Immunol. 141, 463\u2013472 (2018).","journal-title":"J. Allergy Clin. Immunol."},{"key":"61613_CR24","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1016\/j.vaccine.2021.03.073","volume":"39","author":"S Hatziantoniou","year":"2021","unstructured":"Hatziantoniou, S., Maltezou, H. C., Tsakris, A., Poland, G. A. & Anastassopoulou, C. Anaphylactic reactions to mRNA COVID-19 vaccines: A call for further study. Vaccine 39, 2605\u20132607 (2021).","journal-title":"Vaccine"},{"key":"61613_CR25","doi-asserted-by":"crossref","unstructured":"Andersson, N. W., Thiesson, E. M., Hansen, J. V. & Hviid, A. Safety of BA. 4-5 or BA. 1 bivalent mRNA booster vaccines: nationwide cohort study. BMJ 382, e075015 (2023).","DOI":"10.1136\/bmj-2023-075015"},{"key":"61613_CR26","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/cea.13874","volume":"51","author":"P Sellaturay","year":"2021","unstructured":"Sellaturay, P., Nasser, S., Islam, S., Gurugama, P. & Ewan, P. W. Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer\/BioNTech mRNA COVID\u201019 vaccine. Clin. Exp. Allergy 51, 861 (2021).","journal-title":"Clin. Exp. Allergy"},{"key":"61613_CR27","doi-asserted-by":"crossref","unstructured":"Warren, C. M. et al. Assessment of allergic and anaphylactic reactions to mRNA COVID-19 vaccines with confirmatory testing in a US regional health system. JAMA Netw. Open 4, e2125524 (2021).","DOI":"10.1001\/jamanetworkopen.2021.25524"},{"key":"61613_CR28","doi-asserted-by":"publisher","first-page":"222","DOI":"10.9758\/cpn.2023.21.2.222","volume":"21","author":"J Finsterer","year":"2023","unstructured":"Finsterer, J. Neurological adverse reactions to SARS-CoV-2 vaccines. Clin. Psychopharmacol. Neurosci. 21, 222 (2023).","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"61613_CR29","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.5664\/jcsm.10134","volume":"18","author":"A Mahamid","year":"2022","unstructured":"Mahamid, A., Bornstein, R. J. & Amir, H. Pfizer\/BioNTech SARS-CoV-2 vaccine as a potential trigger for the development of narcolepsy: a case report. J. Clin. Sleep Med. 18, 2503\u20132506 (2022).","journal-title":"J. Clin. Sleep Med."},{"key":"61613_CR30","doi-asserted-by":"publisher","first-page":"101077","DOI":"10.1016\/j.cpcardiol.2021.101077","volume":"47","author":"D Hana","year":"2022","unstructured":"Hana, D., Patel, K., Roman, S., Gattas, B. & Sofka, S. Clinical cardiovascular adverse events reported post-COVID-19 vaccination: are they a real risk? Curr. Probl. Cardiol. 47, 101077 (2022).","journal-title":"Curr. Probl. Cardiol."},{"key":"61613_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1123385","volume":"10","author":"W Ou","year":"2023","unstructured":"Ou, W. et al. Acute myocardial infarction after inactivated COVID-19 vaccination: a case report and literature review. Front. Cardiovasc. Med. 10, 1123385 (2023).","journal-title":"Front. Cardiovasc. Med."},{"key":"61613_CR32","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.amjcard.2024.02.015","volume":"218","author":"CS Roberts","year":"2024","unstructured":"Roberts, C. S., Hassan, M. H., Hasson, L., Guileyardo, J. M. & Roberts, W. C. Fatal acute myocardial infarction with normal epicardial coronary arteries shortly following COVID-19 vaccination. Am. J. Cardiol. 218, 68 (2024).","journal-title":"Am. J. Cardiol."},{"key":"61613_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49634-x","volume":"15","author":"S Ip","year":"2024","unstructured":"Ip, S. et al. Cohort study of cardiovascular safety of different COVID-19 vaccination doses among 46 million adults in England. Nat. Commun. 15, 6085 (2024).","journal-title":"Nat. Commun."},{"key":"61613_CR34","doi-asserted-by":"crossref","unstructured":"Hippisley-Cox, J. et al. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. BMJ 374, n1931 (2021).","DOI":"10.1136\/bmj.n1931"},{"key":"61613_CR35","doi-asserted-by":"crossref","unstructured":"Chui, C. S. L. et al. Thromboembolic events and hemorrhagic stroke after mRNA (BNT162b2) and inactivated (CoronaVac) covid-19 vaccination: a self-controlled case series study. EClinicalMedicine 50, 101504 (2022).","DOI":"10.1016\/j.eclinm.2022.101504"},{"key":"61613_CR36","doi-asserted-by":"crossref","unstructured":"Li, X. et al. Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis. BMJ 376, e068373 (2022).","DOI":"10.1136\/bmj-2021-068373"},{"key":"61613_CR37","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1001\/jamacardio.2021.2828","volume":"6","author":"HW Kim","year":"2021","unstructured":"Kim, H. W. et al. Patients with acute myocarditis following mRNA COVID-19 vaccination. JAMA Cardiol. 6, 1196\u20131201 (2021).","journal-title":"JAMA Cardiol."},{"key":"61613_CR38","unstructured":"Marill, M. C. FDA to add myocarditis warning to mRNA COVID-19 vaccines. https:\/\/www.medscape.com\/viewarticle\/953647?form=fpf (2021)."},{"key":"61613_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004056","volume":"19","author":"M Massari","year":"2022","unstructured":"Massari, M. et al. Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study. PLoS Med. 19, e1004056 (2022).","journal-title":"PLoS Med."},{"key":"61613_CR40","doi-asserted-by":"publisher","unstructured":"Husby, A. et al. SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study. BMJ 375, https:\/\/doi.org\/10.1136\/bmj-2021-068665 (2021).","DOI":"10.1136\/bmj-2021-068665"},{"key":"61613_CR41","unstructured":"Centers for Disease Control and Prevention, U.S. Food and Drug Administration. CDC and FDA identify preliminary COVID-19 vaccine safety signal for persons aged 65 years and older. https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/cdc-and-fda-identify-preliminary-covid-19-vaccine-safety-signal-persons-aged-65-years-and-older (2024)."},{"key":"61613_CR42","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1001\/jama.2024.1059","volume":"331","author":"Y Lu","year":"2024","unstructured":"Lu, Y. et al. Stroke risk after COVID-19 bivalent vaccination among US older adults. JAMA 331, 938\u2013950 (2024).","journal-title":"JAMA"},{"key":"61613_CR43","doi-asserted-by":"publisher","first-page":"e53807","DOI":"10.2196\/53807","volume":"10","author":"S Xu","year":"2024","unstructured":"Xu, S. et al. Ischemic stroke after bivalent COVID-19 vaccination: Self-controlled case series study. JMIR Public Health Surveill. 10, e53807 (2024).","journal-title":"JMIR Public Health Surveill."},{"key":"61613_CR44","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1016\/j.vaccine.2024.03.005","volume":"42","author":"Y-W Su","year":"2024","unstructured":"Su, Y.-W. et al. Safety and immunogenicity of heterologous boosting with a bivalent SARS-CoV-2 mRNA vaccine (XBB. 1.5\/BQ. 1) in Chinese participants aged 18 years or more: A randomised, double-blinded, active-controlled phase 1 trial. Vaccine 42, 2438\u20132447 (2024).","journal-title":"Vaccine"},{"key":"61613_CR45","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3390\/vaccines12020118","volume":"12","author":"J Gayed","year":"2024","unstructured":"Gayed, J. et al. Safety and immunogenicity of the monovalent omicron XBB. 1.5-adapted BNT162b2 COVID-19 vaccine in individuals\u2265 12 years old: a phase 2\/3 trial. Vaccines 12, 118 (2024).","journal-title":"Vaccines"},{"key":"61613_CR46","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.hlife.2024.01.005","volume":"2","author":"X Yu","year":"2024","unstructured":"Yu, X. et al. Safety, immunogenicity, and preliminary efficacy of a randomized clinical trial of omicron XBB. 1.5-containing bivalent mRNA vaccine. hLife 2, 113\u2013125 (2024).","journal-title":"hLife"},{"key":"61613_CR47","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1001\/jama.2024.1036","volume":"331","author":"NW Andersson","year":"2024","unstructured":"Andersson, N. W., Thiesson, E. M. & Hviid, A. Adverse events after XBB. 1.5-containing COVID-19 mRNA vaccines. JAMA 331, 1057\u20131059 (2024).","journal-title":"JAMA"},{"key":"61613_CR48","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1093\/jamia\/ocae299","volume":"32","author":"KM Walters","year":"2025","unstructured":"Walters, K. M. et al. National COVID Cohort Collaborative data enhancements: a path for expanding common data models. J. Am. Med. Inform. Assoc. 32, 391\u2013397 (2025).","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"61613_CR49","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1080\/14760584.2022.2020108","volume":"21","author":"X Nie","year":"2022","unstructured":"Nie, X. et al. Self-controlled case series design in vaccine safety: a systematic review. Expert Rev. Vaccines 21, 313\u2013324 (2022).","journal-title":"Expert Rev. Vaccines"},{"key":"61613_CR50","doi-asserted-by":"publisher","first-page":"i4515","DOI":"10.1136\/bmj.i4515","volume":"354","author":"I Petersen","year":"2016","unstructured":"Petersen, I., Douglas, I. & Whitaker, H. Self controlled case series methods: an alternative to standard epidemiological study designs. BMJ 354, i4515 (2016).","journal-title":"BMJ"},{"key":"61613_CR51","unstructured":"FDA. CBER plans for monitoring COVID-19 vaccine safety and effectiveness, https:\/\/stacks.cdc.gov\/view\/cdc\/97349 (2020)."},{"key":"61613_CR52","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1080\/14760584.2023.2260477","volume":"22","author":"A Shabu","year":"2023","unstructured":"Shabu, A. & Nishtala, P. S. Analysis of the adverse events following the mRNA-1273 COVID-19 vaccine. Expert Rev. Vaccines 22, 801\u2013812 (2023).","journal-title":"Expert Rev. Vaccines"},{"key":"61613_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.878081","volume":"10","author":"S Bian","year":"2022","unstructured":"Bian, S. et al. Allergic reactions after the administration of COVID-19 vaccines. Front. Public Health 10, 878081 (2022).","journal-title":"Front. Public Health"},{"key":"61613_CR54","unstructured":"Bonferroni, C. Teoria Statistica Delle Classi e Calcolo Delle Probabilita. (1936)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-61613-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-61613-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-61613-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T11:04:42Z","timestamp":1757243082000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-61613-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["61613"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-61613-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"assertion":[{"value":"31 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6514"}}